BCT303

BCT303 is a sustained-release oral formulation of liothyronine sodium, which is the synthetic form of the thyroid hormone triiodothyronine (T3). Developed by Ipe, LLC, BCT303 is designed to treat hypothyroidism, specifically targeting the limitations of standard immediate-release liothyronine. Immediate-release formulations often result in rapid, supra-physiological peaks of serum T3, which can lead to side effects such as palpitations and anxiety, followed by a quick decline. BCT303 utilizes a sustained-release mechanism to provide a more stable and physiological delivery of T3 over time, aiming to improve symptom management and safety for patients, particularly those who do not respond optimally to levothyroxine (T4) monotherapy.

Other names

sustained-release liothyronine sodiumliothyronine sodium sustained-releaseSR-T3SR-T-3SR-T 3